IAS

Hivr4p 2024, the 5th hiv research for prevention conference, took place in lima, peru, and virtually from 7 to 10 october 2024. Just under 1,400 participants from 77 countries gathered for four days to review the latest advances in hiv prevention science. The hiv research for prevention conference is the only global scientific conference focused exclusively on the challenging and fast-growing field of hiv prevention research. This conference fosters interdisciplinary knowledge exchange on hiv vaccines, microbicides, prep, treatment as prevention and biomedical interventions, as well as their social and behavioural implications. At hivr4p 2024, results from purpose 2 showed that injectable lenacapavir long[1]acting pre-exposure prophylaxis (prep) was highly effective in preventing hiv acquisition in men who have sex with men and trans women. Researchers submitted a total of 1,740 abstracts to hivr4p 2024 (1,548 regular abstracts and 192 late-breaker abstracts) and 827 were accepted for presentation, including 127 oral abstracts, 21 late-breaking oral abstracts, 280 poster abstracts and 399 e-poster abstracts. Research was presented in 16 invited-speaker sessions, 26 oral abstract sessions and 26 satellites.